

September 30, 2014  
Stuart D. Russell, MD  
Johns Hopkins Hospital  
1800 Orleans Street  
Sheikh Zayed Tower, Suite 7125  
Baltimore, MD 21287, United States



Re: Response to reviewers, manuscript 13832, ID # 00207451

Dear Editor,

Thank you for your consideration of our manuscript entitled "Arginine vasopressin as a target in the treatment of acute heart failure" for publication in the *World Journal of Cardiology*. Enclosed you will find our edited manuscript in Word Format, entitled 13832-edited.docx in response to the reviewers.

**Title:** Arginine vasopressin as a target in the treatment of acute heart failure

**Authors:** Nisha A Gilotra, Stuart D Russell

**ESPS Manuscript #:** 13832

**ID #:** 00207451

The manuscript has been improved according to the suggestions of the reviewers. Changes are highlighted within the document.

1) *Table 1 has been referenced within the text.*

2) Reviewer **00502903**: "This is a very well-written review of the vaptan class of pharmaceuticals. I have only 2 comments.

1. p.6, "More recent trials have demonstrated similar safety endpoints however to clear benefit to nesiritide therapy." Please clarify this sentence. Do you mean, "More recent trials have demonstrated similar safety endpoints, but no clear benefit to nesiritide therapy."

- *This typo has been corrected as suggested by the reviewer.*

2. p.10, last sentence, should read "when compared to a V2 selective antagonist, increased the first derivative..." (not decreased)

- *This has been modified as suggested above to read "increased".*

3) Reviewer **00227654**: "This review is timely and well written, providing a comprehensive and succinct clinical review. Minor point - please rewrite final sentence of Conclusions section - it is confusing as currently written."

- *This sentence has been modified and clarified as follows:*

- *Prior language:* "With results of ongoing vasopressin antagonist studies, use of these agents may change the treatment approach in both the inpatient and outpatient settings however there is still work to be done to decrease long-term morbidity and mortality in this patient population, which the vaptans do not seem to promise."

- *Changed to:* "Results from ongoing studies of vasopressin antagonists may change the treatment approach in both inpatient and outpatient heart failure patients. However, there is still work to

be done to decrease long-term morbidity and mortality in this patient population, which the vaptans do not seem to promise.”

Thank you very much for your consideration of our revised manuscript for publication.

Sincerely yours,

Nisha A Gilotra, MD

Stuart D Russell, MD

Division of Cardiology, Johns Hopkins Hospital  
1800 Orleans Street  
Sheikh Zayed Tower, Suite 7125  
Baltimore, MD 21287, United States  
srusse14@jhmi.edu  
Telephone: 410-955-5708, Fax: 410-955-3478